Updated recommendations for the treatment of light-chain amyloidosis from the Swiss Amyloidosis Network.

IF 1.9 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Swiss medical weekly Pub Date : 2025-07-17 DOI:10.57187/s.4219

Max J Rieger, Andreas J Flammer, Sabine Gerull, Thomas Pabst, Holger W Auner, Kaveh Samii, Felicitas Hitz, Ulrich Mey, Veronika Ballova, Raphael Battegay, Giorgia Melli, Dominik Benz, Yakup Yakupoglu, Christoph Gräni, Regina Schläger, Sarah Hugelshofer, Annina Studer, Luca Oechslin, Adam Bakula, Thomas M Suter, Julia Leo-Stickelberger, Manuela Averiamo, Thomas Fehr, Hans H Jung, Natallia Laptseva, Robert Manka, Axel Rüfer, Adrian Schmidt, Harald Seeger, Beat Müllhaupt, Simon F Stämpfli, Carmen De Ramon Ortiz, Marie Théaudin, Bernhard Gerber, Rahel Schwotzer

{"title":"Updated recommendations for the treatment of light-chain amyloidosis from the Swiss Amyloidosis Network.","authors":"Max J Rieger, Andreas J Flammer, Sabine Gerull, Thomas Pabst, Holger W Auner, Kaveh Samii, Felicitas Hitz, Ulrich Mey, Veronika Ballova, Raphael Battegay, Giorgia Melli, Dominik Benz, Yakup Yakupoglu, Christoph Gräni, Regina Schläger, Sarah Hugelshofer, Annina Studer, Luca Oechslin, Adam Bakula, Thomas M Suter, Julia Leo-Stickelberger, Manuela Averiamo, Thomas Fehr, Hans H Jung, Natallia Laptseva, Robert Manka, Axel Rüfer, Adrian Schmidt, Harald Seeger, Beat Müllhaupt, Simon F Stämpfli, Carmen De Ramon Ortiz, Marie Théaudin, Bernhard Gerber, Rahel Schwotzer","doi":"10.57187/s.4219","DOIUrl":null,"url":null,"abstract":"<p><p>Since the publication of the first Swiss recommendations on systemic light-chain amyloidosis in 2020, treatment strategies have evolved. As a result of the third joint meeting of the Swiss Amyloidosis Network, a multidisciplinary and multicentre Swiss clinical consortium, in 2024, recommendations for the treatment of light-chain amyloidosis were updated. They discuss the role of the new standard first-line protocol Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone (Dara-CyBorD), the timing and indication of high-dose treatment and potential second-line strategies as well as emerging treatment options, with a special focus on multidisciplinary supportive care measures. The update represents a synopsis of current evidence and expert consensus and intends to provide general treatment guidance tailored to the Swiss healthcare system. Nonetheless, treatment decisions should always be personalised and involve a multidisciplinary approach. This update replaces the previous \"therapeutic recommendations\" while the previous \"diagnostic recommendations\" remain valid.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"155 ","pages":"4219"},"PeriodicalIF":1.9000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Swiss medical weekly","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.57187/s.4219","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Since the publication of the first Swiss recommendations on systemic light-chain amyloidosis in 2020, treatment strategies have evolved. As a result of the third joint meeting of the Swiss Amyloidosis Network, a multidisciplinary and multicentre Swiss clinical consortium, in 2024, recommendations for the treatment of light-chain amyloidosis were updated. They discuss the role of the new standard first-line protocol Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone (Dara-CyBorD), the timing and indication of high-dose treatment and potential second-line strategies as well as emerging treatment options, with a special focus on multidisciplinary supportive care measures. The update represents a synopsis of current evidence and expert consensus and intends to provide general treatment guidance tailored to the Swiss healthcare system. Nonetheless, treatment decisions should always be personalised and involve a multidisciplinary approach. This update replaces the previous "therapeutic recommendations" while the previous "diagnostic recommendations" remain valid.

查看原文本刊更多论文

瑞士淀粉样变性网络对轻链淀粉样变性治疗的最新建议。

自2020年瑞士发布首个系统性轻链淀粉样变性建议以来，治疗策略发生了变化。作为瑞士淀粉样变性网络（一个多学科和多中心的瑞士临床联盟）第三次联合会议的结果，于2024年更新了治疗轻链淀粉样变性的建议。他们讨论了新标准一线方案达拉单抗、环磷酰胺、硼替佐米、地塞米松（Dara-CyBorD）的作用，大剂量治疗的时机和适应症，潜在的二线策略以及新兴的治疗方案，特别关注多学科支持治疗措施。该更新代表了当前证据和专家共识的摘要，并打算提供适合瑞士医疗保健系统的一般治疗指导。尽管如此，治疗决定应该始终是个性化的，并涉及多学科方法。此更新取代了之前的“治疗建议”，而之前的“诊断建议”仍然有效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Swiss medical weekly 医学-医学：内科

CiteScore

5.00

自引率

0.00%

发文量

审稿时长

3-8 weeks

期刊介绍： The Swiss Medical Weekly accepts for consideration original and review articles from all fields of medicine. The quality of SMW publications is guaranteed by a consistent policy of rigorous single-blind peer review. All editorial decisions are made by research-active academics.